Inderjit Kaul

Inderjit Kaul currently works at Minerva Neurosciences, Inc., as Director from 2025, Oscient Pharmaceuticals Corp., as Vice President-Medical & Regulatory Affairs from 2010, and Draig Therapeutics Ltd., as Chief Medical Officer.
Dr. Kaul also formerly worked at PAREXEL International Corp., as Director-Medical Services in 1992, G.D.
Searle & Co., Inc., as Director-International Medical Operations, Boehringer Ingelheim Pharmaceuticals, Inc., as Associate Director-Clinical Research in 1994, Asiatic Clinical Research Pvt Ltd., as Director, Candela Corp., as Principal in 1990, Medical & Technical Research Associates, Inc., as Vice President-Clinical & Medical Affairs in 1998, Abt Associates, Inc., as Vice President, Artisan Pharma, Inc., as Chief Medical Officer, Bristol Myers Squibb Co., as SVP-Late Stage Clinical Development from 2024 to 2025, and Karuna Therapeutics, Inc., as Vice President-Clinical Development.
Dr. Kaul received his graduate degree and doctorate degree from Harvard University and undergraduate degree from the University of Kashmir.